Genitourinary solid tumors: cross-border specialty drug access for international patients

Quick orientation

Prostate, kidney, bladder, and other GU cancers collectively are among the leading cancer diagnoses globally. Prostate cancer alone has approximately 1.4 million new cases per year worldwide.

Typical age of onset. Most commonly in adults aged 50 and older.

Severity tiers. Severity depends on tumor type, stage, and molecular profile.

Why specialty drugs for Genitourinary solid tumors are hard to access internationally

Several newer FDA approvals in advanced prostate cancer, urothelial cancer, and renal cell carcinoma are not yet widely registered. Targeted radioligand therapies for prostate cancer have particularly complex supply chains.

Treatments approved by the FDA

• Xtandi (enzalutamide) — FDA approval: 2012. Mechanism: Androgen receptor inhibitor. Route: Oral once daily. US WAC ballpark: Approximately USD 200,000 per year. Country pricing: UAE · Saudi Arabia · India · Egypt.
• Welireg (belzutifan) — FDA approval: 2021. Mechanism: HIF-2 alpha inhibitor for advanced RCC and VHL-associated tumors. Route: Oral once daily. US WAC ballpark: Approximately USD 250,000 per year. Country pricing: India · Oman.
• Akeega (niraparib and abiraterone acetate fixed-dose combination) — FDA approval: 2023. Mechanism: PARP inhibitor plus AR inhibitor combination. Route: Oral. US WAC ballpark: Approximately USD 220,000 per year. Country pricing: UAE · Saudi Arabia · India · Qatar · Kuwait · Egypt · Jordan · Bahrain.
• Tivdak (tisotumab vedotin-tftv) — FDA approval: 2021. Mechanism: Tissue factor-directed antibody-drug conjugate (cervical cancer label; relevant adjacent GYN). Route: Intravenous infusion every 3 weeks. US WAC ballpark: Approximately USD 210,000 per year. Country pricing: UAE · Bahrain.

Cross-border pathways used for Genitourinary solid tumors

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Expanded Access Program (EAP)
• Compassionate Use
• Personal Import Scheme

What your physician needs to know

• Confirm tumor type and molecular profile.
• Document prior systemic therapy and castration status (prostate).
• Multidisciplinary GU oncology team co-manages.
• Watch for AR pathway and PARP class adverse events.

Common questions

Are these drugs registered in my country?

Registration varies. We confirm by destination.

How is molecular profile assessed?

HRR/BRCA testing, MMR, and other markers as clinically indicated.

Can targeted therapy be combined?

Several approved combinations exist. Your oncologist decides.

How long does shipment take?

Five to fifteen business days from prescription receipt.

What documents are required?

Oncologist's prescription, pathology, imaging, and treatment history.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Genitourinary solid tumors, our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Genitourinary solid tumors

Reserved for you.